The Multiple Myeloma Research Foundation is hoping that an open-access research portal containing detailed longitudinal clinical and genomic data from multiple myeloma patients will spur collaborative research that advances much needed molecularly-targeted treatments.
Originally published Aug. 13.
The combined sales from Roche's treatments for HER2-positive breast cancer took the lead for pharmacogenomically targeted cancer drugs during the second quarter.
While RNAi drug developers continue to pursue major indications such as cancer and hepatitis C, a number of these companies are looking to niche diseases as good opportunities to apply the gene-silencing technology.
Two new personalized treatment options are now available for patients with metastatic or unresectable melanoma whose tumors harbor mutations in the BRAF gene.
NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today announced the signing of a collaborative agreement with Bristol-Myers Squibb for the use of Adaptive's technology to discover immunological biomarkers in cancer.
A group of Australian researchers has identified a set of plasma proteins that could help predict patient levels of the Alzheimer's disease-associated molecule beta-amyloid.
Qiagen said this week that GE Healthcare subsidiary Clarient will offer Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Opko Health said this week that it has expanded its collaboration with drugmaker Bristol-Myers Squibb to use its protein biomarker discovery platform to identify markers predictive of patient response to several BMS therapeutics.
NEW YORK (GenomeWeb News) – Opko Health said today that it has expanded a collaboration with Bristol-Myers Squibb to include biomarker discovery for pharmacogenomic tests for use in treating Alzheimer's disease.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.